NK细胞治疗晚期肝癌,患者肿瘤大幅缩小,生存期有望超5年[2]! 专注于分享癌症靶向分子或精准治疗的国际知名期刊OncoTargets and Therapy曾报道的这个临床案例,更是有力地证明了NK细胞治疗在晚期肝细胞癌患者中的显著成效: 一名59岁的男性晚期弥漫...
https://www.dovepress.com/comparison-of-autogeneic-and-allogeneic-natural-killer-cells-immunothe-peer-reviewed-fulltext-article-OTT [2]Bae W K,et al.A phase I study of locoregional high-dose autologous natural killer cell therapy with hepatic arterial infusion chemotherapy in patients with locall...
https://www.nature.com/articles/s41420-024-01815-9 [2]Liu F,et al.Advances in CAR-NK cell therapy for lung cancer: is it a better choice in the future? Front Oncol. 2024 May 28;14:1390006. https://www.ncbi....
神刊CA：近50%癌症患者因感染死亡！NK细胞疗法抗癌又抗感染！在癌症治疗领域，感染已成为影响患者生存质量的重大障碍。美国癌症学会主办的CA-A Cancer Journal for Clinicians（IF：503.1）曾发表研究指出，感染是癌症患者最常见的并发症之一，也是第二大死亡原因，大约50%的癌症患者最终因感染而失去生命。癌症患者为何...
[3]Zhang X,et al.Cytokine release syndrome after modified CAR-NK therapy in an advanced non-small cell lung cancer patient: a case report[J]. Cell Transplantation,2022,31:09636897221094244. https://journals.sagepub.com/doi/full/10.1177/09636897221094244 ...
研究包括了临床前模型的实验和一项单臂、开放标签的1期临床试验。相关内容以“safety and feasibility of 4-1bb co-stimulated cd19-specific car-nk cell therapy in refractory/relapsed large b cell lymphoma: a phase 1 trial”为题发表在《nature cancer》上。【主要内容】图1 cd19-bbz car-nk细胞的构建...
NK细胞疗法创新研发3大方向 从研发模式来看，NK细胞疗法的研发正朝着多个方向迅速发展。目前，基于NK细胞的创新疗法的临床药物开发主要有非工程化的NK细胞、工程化的NK细胞（例如CAR-NK细胞疗法、TCR-NK细胞疗法等）以及NK细胞联合疗法（NK细胞接合器）。近日，《Cancer Cell》上发表的研究指出，通过IL-21工程化的NK...
J].Blood,2023,142:2097.https://ash.confex.com/ash/2023/webprogram/Paper173582.html [3]https://www.drugtargetreview.com/article/112476/car-nk-cells-promising-for-cancer-therapy/ [4]https://www.dana-farber.org/newsroom/features/making-natural-killer-cells-smarter-to-improve-cell-therapy ...
最近，针对应用NK细胞治疗癌症的研究综述《NK Cell Therapy: A Rising Star in Cancer Treatment》发表于国际肿瘤核心期刊《Cancers》。研究发现，癌症组织中的 NK 细胞数量低于正常水平，这种情况下有助于癌细胞的生长。另外,NK细胞免疫功能损害，对抗癌免疫有干扰作用。因此，正开展大量研究来发展基于提高NK细胞数目、...
[3]Li C,et al.Robo1-specific chimeric antigen receptor natural killer cell therapy for pancreatic ductal adenocarcinoma with liver linkstasis[J]. Journal of Cancer Research and Therapeutics, 2020, 16(2): 393-396.https://journals.lww.com/cancerjournal/fulltext/2020/16020/robo1_specific_chimeric...